- Home
- CURI vs HURA Comparison
CURI vs HURA Comparison
Compare CURI & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CURI | HURA |
|---|---|---|
| Founded | N/A | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.7M | 160.5M |
| IPO Year | 2019 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CURI | HURA |
|---|---|---|
| Price | $2.63 | $2.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.83 | ★ $9.50 |
| AVG Volume (30 Days) | ★ 1.6M | 255.5K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 10.36% | N/A |
| EPS Growth | ★ 54.17 | 47.93 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $78,043,000.00 | N/A |
| Revenue This Year | $14.91 | N/A |
| Revenue Next Year | $12.91 | N/A |
| P/E Ratio | $21.33 | ★ N/A |
| Revenue Growth | ★ 9.52 | N/A |
| 52 Week Low | $2.30 | $0.41 |
| 52 Week High | $5.51 | $3.43 |
Technical Indicators
Market Signals| Indicator | CURI | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 45.26 | 47.72 |
| Support Level | $2.32 | $1.99 |
| Resistance Level | $3.49 | $2.20 |
| Average True Range (ATR) | 0.26 | 0.18 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 5.28 | 25.42 |
Price Performance
Historical ComparisonAbout CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.